Total Payments
$1.4M
2021 Payments
$16,774
Companies
14
Transactions
436
Payment Breakdown by Category
Research$1.3M (96.9%)
Consulting$30,853 (2.2%)
Other$6,400 (0.5%)
Travel$4,701 (0.3%)
Food & Beverage$1,785 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 395 | 96.9% |
| Consulting Fee | $30,853 | 9 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,400 | 2 | 0.5% |
| Travel and Lodging | $4,701 | 14 | 0.3% |
| Food and Beverage | $1,785 | 16 | 0.1% |
Payments by Type
Research
$1.3M
395 transactions
General
$43,739
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $510,156 | 201 | $0 (2020) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $508,427 | 31 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $116,364 | 130 | $0 (2018) |
| Allergan Inc. | $93,360 | 7 | $0 (2017) |
| Avanir Pharmaceuticals, Inc. | $73,657 | 17 | $0 (2021) |
| H. Lundbeck A S | $31,224 | 5 | $0 (2018) |
| Takeda Development Center Americas, Inc. | $19,013 | 6 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $10,708 | 4 | $0 (2020) |
| F. Hoffmann-La Roche AG | $8,241 | 8 | $0 (2019) |
| PFIZER INC. | $7,924 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $16,774 | 5 | Avanir Pharmaceuticals, Inc. ($16,774) |
| 2020 | $545,862 | 85 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($361,808) |
| 2019 | $329,092 | 126 | ACADIA Pharmaceuticals Inc ($230,099) |
| 2018 | $107,621 | 48 | ACADIA Pharmaceuticals Inc ($45,829) |
| 2017 | $389,717 | 172 | ACADIA Pharmaceuticals Inc ($93,842) |
All Payment Transactions
436 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2021 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: 18-AVP-786-207 | ||||||
| 05/21/2021 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,367.88 | Research |
| Study: 18-AVP-786-207 | ||||||
| 04/30/2021 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $7,721.86 | Research |
| Study: 18-AVP-786-207 | ||||||
| 02/18/2021 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,655.54 | Research |
| Study: 18-AVP-786-207 | ||||||
| 01/15/2021 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,028.82 | Research |
| Study: 18-AVP-786-207 | ||||||
| 12/19/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $564.96 | Research |
| Study: ACP-103-059/ACP-103-055 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/18/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/02/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $287.50 | Research |
| Study: ACP-103-035 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/29/2020 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,149.04 | Research |
| Study: 18-AVP-786-207 | ||||||
| 09/24/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $5,000.00 | Research |
| Study: A PHASE 2, 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF 3 DOSE LEVELS OF TAK-831 IN ADJUNCTIVE TREATMENT OF ADULT SUBJECTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | ||||||
| 09/24/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A PHASE 2, 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF 3 DOSE LEVELS OF TAK-831 IN ADJUNCTIVE TREATMENT OF ADULT SUBJECTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | ||||||
| 09/24/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A PHASE 2, 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF 3 DOSE LEVELS OF TAK-831 IN ADJUNCTIVE TREATMENT OF ADULT SUBJECTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | ||||||
| 09/22/2020 | ACADIA Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,925.00 | Research |
| Study: ACP-103-035 | ||||||
| 09/21/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $5,702.76 | Research |
| Study: ACP-103-059 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/21/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,561.52 | Research |
| Study: ACP-103-055 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/07/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $18,688.32 | Research |
| Study: ACP-103-059 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 08/25/2020 | ACADIA Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,131.25 | Research |
| Study: ACP-103-035 | ||||||
| 08/25/2020 | ACADIA Pharmaceuticals Inc | — | — | Cash or cash equivalent | $287.50 | Research |
| Study: ACP-103-035 | ||||||
| 08/19/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $3,123.04 | Research |
| Study: ACP-103-055 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/20/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $14,652.42 | Research |
| Study: ACP-103-055 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/25/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $8,896.34 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/25/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $268.75 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/25/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $256.25 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/25/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $62.50 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/25/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $50.00 | Research |
| Study: ACP-103-038 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-059 | ACADIA Pharmaceuticals Inc | $209,885 | 15 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $120,863 | 1 |
| ACP-103-038 | ACADIA Pharmaceuticals Inc | $99,891 | 101 |
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $92,838 | 13 |
| A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $79,662 | 1 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $65,229 | 1 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $64,878 | 1 |
| 18-AVP-786-207 | Avanir Pharmaceuticals, Inc. | $56,281 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $54,035 | 2 |
| PEDIATRIC OPEN-LABEL EXTENSION STUDY | Sunovion Pharmaceuticals Inc. | $53,792 | 92 |
| A LONG-TERM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS MAINTENANCE TREATMENT IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $52,063 | 1 |
| ACP-103-035 | ACADIA Pharmaceuticals Inc | $50,308 | 41 |
| ACP-103-055 | ACADIA Pharmaceuticals Inc | $46,770 | 6 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS (13-17 YEARS OLD) WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $32,696 | 2 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD | H. Lundbeck A S | $30,040 | 2 |
| A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM (IE, MAINTENANCE) EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $26,128 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OPC-34172 in the Treatment of Adolescent Patients with Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $24,155 | 1 |
| A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures | Sunovion Pharmaceuticals Inc. | $23,883 | 12 |
| A MULTICENTER, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED PARALLEL-GROUP EVALUATION OF THE SAFETY AND EFFICACY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $22,923 | 1 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22,894 | 4 |
| DASOTRALINE ADULT ADHD STUDY | Sunovion Pharmaceuticals Inc. | $18,017 | 6 |
| A Long-Term, Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescent Patients with Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $17,385 | 2 |
| 15-AVP-786-202 | Avanir Pharmaceuticals, Inc. | $16,758 | 1 |
| LURASIDONE PEDIATRIC BIPOLAR STUDY | Sunovion Pharmaceuticals Inc. | $16,359 | 12 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIXED-DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I DEPRESSION | Allergan Inc. | $14,181 | 1 |
| A PHASE 2, 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF 3 DOSE LEVELS OF TAK-831 IN ADJUNCTIVE TREATMENT OF ADULT SUBJECTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Takeda Pharmaceuticals U.S.A., Inc. | $10,708 | 4 |
| ACP-103-034 | ACADIA Pharmaceuticals Inc | $7,448 | 2 |
| PEDIATRIC SCHIZOPHRENIA EFFICACY AND SAFETY STUDY | Sunovion Pharmaceuticals Inc. | $3,471 | 6 |
| Evaluation of SPN-812 ER 100 and 200 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo- Controlled, Pivotal Trial | Supernus Pharmaceuticals, Inc. | $2,048 | 5 |
| ACP-103-059/ACP-103-055 | ACADIA Pharmaceuticals Inc | $1,935 | 20 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,453 | 7 |
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age | H. Lundbeck A S | $1,184 | 3 |
| GLYX-13 OLE FOR MDD IV, 2 TREATMENT ARM 225MG OR 450MG | Allergan Inc. | $1,091 | 1 |
| ACP-103-059-055 | ACADIA Pharmaceuticals Inc | $1,082 | 3 |
| A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug | Sunovion Pharmaceuticals Inc. | $842.82 | 2 |
| AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | Allergan Inc. | $837.76 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS 13-17 YEARS OLD WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $531.82 | 5 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $489.77 | 4 |
| AN OPEN-LABEL LONG-TERM SAFETY STUDY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $292.00 | 1 |
About Dr. Sarah Atkinson, MD
Dr. Sarah Atkinson, MD is a General Practice healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285859306.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarah Atkinson, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $16,774 received in 2021. These payments were reported across 436 transactions from 14 companies. The most common payment nature is "" ($1.3M).
Ad
Practice Information
- Specialty General Practice
- Location Rochester, NY
- Active Since 04/16/2007
- Last Updated 02/13/2014
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1285859306
Products in Payments
- NUPLAZID (Drug) $505,310
- REXULTI (Drug) $214,335
- ABILIFY (Drug) $79,662
- LATUDA (Drug) $73,622
- TRINTELLIX (Drug) $31,224
- Aptiom (Drug) $24,725
- VIIBRYD (Drug) $23,215
- Trintellix (Drug) $19,013
- DASOTRALINE (Drug) $18,017
- VRAYLAR (Drug) $14,181
- Non-Covered Product (Drug) $7,141
- PRISTIQ (Drug) $6,400
- GEODON (Drug) $1,524
- BREXPIPRAZOLE (Drug) $178.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Rochester
Steven Ytterberg, M.d, M.D
General Practice — Payments: $127,642
General Practice $127,642
Adrian Vella, M.d, M.D
General Practice — Payments: $53,347
General Practice $53,347
Matthew Drake, Md, MD
General Practice — Payments: $38,591
General Practice $38,591
Yogish Kudva, Mbbs, MBBS
General Practice — Payments: $35,396
General Practice $35,396
Michael Jensen, M.d, M.D
General Practice — Payments: $34,497
General Practice $34,497
Dr. Frank Lamar, D.d.s, D.D.S
General Practice — Payments: $34,205
General Practice $34,205